A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Trial Profile

A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs CMB 305 (Primary)
  • Indications Non-small cell lung cancer; Ovarian cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Immune Design
  • Most Recent Events

    • 30 Jun 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
    • 30 Jun 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top